INKON Life(SZ:300143)2026-03-30 13:04Financial Performance - In 2025, the company achieved operating revenue of CNY 1.886 billion, a year-on-year increase of 20.93% [3] - The net profit attributable to shareholders was CNY 68.54 million, a decrease of 40.62%, primarily due to adjustments related to the acquisition of Saint Nor [3] - Excluding non-recurring items, the net profit attributable to shareholders increased by 28.50% to CNY 107 million [3] - The net cash flow from operating activities was CNY 341 million, up 31.47% year-on-year [3] Medical Services - The medical services segment generated revenue of CNY 1.501 billion, with a patient volume of 604,100, reflecting an 11% year-on-year growth [4] - Surgical volume increased by 71%, with advanced surgeries (level 3 and 4) accounting for 78% of total surgeries, up 7 percentage points [4] - The company completed a strategic acquisition of Changsha Kexin Tumor Hospital, contributing CNY 622 million to tumor business revenue, which represented 41.5% of medical service income [3][4] Technological Innovation - The company has integrated AI capabilities into key diagnostic and treatment processes, reducing preoperative planning time by approximately 80% and decreasing postoperative hospital stays by 1.5 days [7] - AI-enabled services have achieved a patient Net Promoter Score (NPS) of 93%, surpassing the industry average of 90% [7] Medical Devices - The medical device segment reported revenue of CNY 380 million, a year-on-year increase of 14.30% [9] - The acquisition of Saint Nor and Uni Medical exceeded performance targets, with Saint Nor achieving a net profit of CNY 87.40 million, a completion rate of 127.47% for performance commitments [10] - The overseas revenue for medical devices reached CNY 104 million, up 20.24% year-on-year [10] Strategic Development - The company plans to continue expanding its regional medical center layout and pursue "ecological mergers" to enhance synergy [20] - Focus areas for future acquisitions include imaging enhancement, tumor treatment, life support, and blood circulation [20] - The company is also developing a comprehensive health management platform for cancer patients, which is currently in the testing phase [12]